MannKind (MNKD) said Monday it has discontinued its phase 3 trial evaluating MNKD-101, a nebulized clofazimine inhalation suspension, for the treatment of nontuberculous mycobacterial lung disease.

The company said no sputum culture conversions were observed from the first 46 participants who completed the double-blind treatment phase and the Data Safety Monitoring Board agreed with the decision to discontinue the trial due to futility.

MannKind said the the outcome does not affect plans for MNKD-102, its dry powder inhalation clofazimine, which remains under consideration for future clinical development.

MannKind shares were down 7.5% in recent Monday premarket activity.